FSCN3

Across TCGA pan-cancer cohorts, FSCN3 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of FSCN3’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where FSCN3 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types FSCN3 is over-expressed in tumor, although a few such as THCA and BRCA show the opposite, repressed pattern.

KIRC, THCA, and BRCA are the cancer types where FSCN3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FSCN3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	All	All	+0.045	<.001	9	view →
THCA	Female	All	−0.098	<.001	7	view →
BRCA	All	III,IV	−0.155	<.001	6	view →
KICH	All	All	−0.062	<.001	4	view →
LUAD	All	All	−0.062	.012	4	view →
LIHC	Female	All	+0.029	.036	3	view →
CHOL	All	All	+0.092	.012	2	view →
LUSC	Male	All	−0.049	.037	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

FSCN3–KIRC

Open the KIRC breakdown →